Health
Eli Lilly’s Stock Has Swung on Alzheimer’s Drug Developments. What Investors Need to Know. – Barron’s
Eli Lilly may have recently disappointed investors with a study’s data, but the approach being taken by it and other drugmakers to treat the disease seems to be…
When
Eli Lilly
presented the results of a small study of its Alzheimers disease therapy donanemab last weekend, investors were hoping for a miracle. It didnt materialize, and Lilly (ticker: LLY) shares, which had run up 11.7% when the company previewed the study back in January, slid 11.6% by the end of trading on Thursday.Those swings in the stock dont tell the real story of donanemab. The data that Lilly presented last Saturday were positive for Alzheimers drug development in general, and for…
-
Noosa News11 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
General14 hours agoEnglish springer spaniels Kelly and Milo helping fight dieback in Western Australia
-
General13 hours agoHomicide Squad investigating ‘suspicious’ death of 84yo woman in Sydney suburb of Melonba
-
Noosa News3 hours agoNRL grand final quick hits: Reece Walsh creates magic after avoiding sin bin as Broncos survive Hunt, Reynolds injuries to win premiership